MANE
Veradermics, Incorporated · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2026
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Wealth Enhancement Advisory… | 20.32K | New | $2.57M | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Wealth Enhancement Advisory… | $2.57M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 79 holders, 24.94M shares, $1.57B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 690.60K sh · $74.07M
Director · 59.40K sh · $6.37M
Officer · 16.31K sh · $1.75M
Officer · 16.77K sh · $1.82M
Officer · 2.35K sh · $256,730
Officer · 161 sh · $17,916
Officer · 7.92K sh · $844,930
Director · 80.00K sh · $8.58M
Director · 5.00K sh · $541,200
Director · 15.00K sh · $1.59M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology
8.8% of class · View original SEC filing ↗
4.9% of class · View original SEC filing ↗